AXIM Biotechnologies, Inc. (AXIM)
- Previous Close
0.0080 - Open
0.0095 - Bid 0.0073 x --
- Ask 0.0080 x --
- Day's Range
0.0095 - 0.0097 - 52 Week Range
0.0050 - 0.0400 - Volume
41,000 - Avg. Volume
422,715 - Market Cap (intraday)
2.769M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Aug 21, 2024 - Aug 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
www.aximbiotech.comRecent News: AXIM
Performance Overview: AXIM
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AXIM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AXIM
Valuation Measures
Market Cap
2.33M
Enterprise Value
8.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.51
Price/Book (mrq)
--
Enterprise Value/Revenue
104.66
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.30%
Return on Equity (ttm)
--
Revenue (ttm)
85.1k
Net Income Avi to Common (ttm)
-5.59M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
96.71k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.78M